| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
Dibenzyl N,N-diisopropylphosphoramidite does not have a defined pharmacological target. It is a phosphoramidite reagent used in organic synthesis for the preparation of phosphopeptides and for the synthesis of GDP (guanosine diphosphate) analogs such as SML-8-73-1. The compound is a key reagent in phosphorylation chemistry.
|
|---|---|
| ln Vitro |
To make phosphopeptides, utilize dibenzyl N,N-diisopropylphosphoramidite. The GDP (guanosine diphosphate) counterpart SML-8-73-1 is synthesized using it. For nucleotide conjugation, it can be applied.
In vitro, Dibenzyl N,N-diisopropylphosphoramidite is used as a phosphoramidite reagent for the preparation of phosphopeptides. It may also be used for the synthesis of GDP analogs such as SML-8-73-1. As a phosphoramidite, it is a key reagent in the synthesis of phosphorylated compounds and nucleotide analogs for biochemical research. |
| ln Vivo |
In vivo activity data for Dibenzyl N,N-diisopropylphosphoramidite itself are not available, as the compound is a chemical reagent used for synthesis. It is not intended for in vivo administration. The compound may be used in the synthesis of GDP analogs that are subsequently evaluated in vivo, but the reagent itself has no established in vivo profile.
|
| Enzyme Assay |
For in vitro chemical synthesis, Dibenzyl N,N-diisopropylphosphoramidite is used as a phosphitylating reagent. The compound is dissolved in anhydrous solvents (e.g., DCM, THF) and reacted with alcohols or other nucleophiles in the presence of an activator (e.g., tetrazole) to form phosphite triesters, which can be oxidized to phosphates. The compound has a purity of ≥98.0% (nonaqueous titration).
|
| Cell Assay |
For in vitro biochemical experiments, Dibenzyl N,N-diisopropylphosphoramidite is used in the synthesis of phosphorylated compounds and nucleotide analogs. The compound is not used directly in cell-based assays but is used to prepare test compounds that are subsequently evaluated in biochemical and cell-based studies.
|
| Animal Protocol |
In vivo animal studies using Dibenzyl N,N-diisopropylphosphoramidite are conducted on the final compounds synthesized from it, not on the reagent itself. For GDP analogs such as SML-8-73-1 derived from this reagent, efficacy studies would be performed in appropriate animal models. Standard in vivo protocols involve administration to rodents via appropriate routes with pharmacokinetic and pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Dibenzyl N,N-diisopropylphosphoramidite as a standalone compound are not characterized in the literature. The compound has a molecular weight of 345.42 g/mol and is a liquid with a density of 1.028 g/mL and a flash point of 70°C. As a phosphoramidite, it is moisture-sensitive and should be handled under inert atmosphere.
|
| Toxicity/Toxicokinetics |
This compound is moisture-sensitive and should be handled with appropriate laboratory safety precautions. As a phosphoramidite, it may cause skin and eye irritation. The compound has a flash point of 70°C and should be stored away from heat and open flames. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood under inert atmosphere.
|
| Additional Infomation |
The structure is described in the first document; it is used for phosphorylation of hydroxyl groups on unprotected amino acid side chains.
Dibenzyl N,N-diisopropylphosphoramidite (CAS 108549-23-1) is a research-grade chemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are as a phosphoramidite reagent for the preparation of phosphopeptides and for the synthesis of GDP analogs such as SML-8-73-1. The compound is a key reagent in phosphorylation chemistry and nucleotide analog synthesis. No clinical trials or approved indications exist for this compound. |
| Molecular Formula |
C20H28NO2P
|
|---|---|
| Molecular Weight |
345.42
|
| Exact Mass |
345.185
|
| CAS # |
108549-23-1
|
| PubChem CID |
196621
|
| Appearance |
Colorless to light yellow liquid（Density：1.028 g/cm3）
|
| Density |
1.028 g/mL at 25 °C(lit.)
|
| Boiling Point |
382.0±31.0 °C at 760 mmHg
|
| Flash Point |
184.8±24.8 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
n20/D 1.535(lit.)
|
| LogP |
6.82
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
24
|
| Complexity |
296
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(N(C(C)C)P(OCC1=CC=CC=C1)OCC2=CC=CC=C2)C
|
| InChi Key |
ANPWLBTUUNFQIO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H28NO2P/c1-17(2)21(18(3)4)24(22-15-19-11-7-5-8-12-19)23-16-20-13-9-6-10-14-20/h5-14,17-18H,15-16H2,1-4H3
|
| Chemical Name |
N-bis(phenylmethoxy)phosphanyl-N-propan-2-ylpropan-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8950 mL | 14.4751 mL | 28.9503 mL | |
| 5 mM | 0.5790 mL | 2.8950 mL | 5.7901 mL | |
| 10 mM | 0.2895 mL | 1.4475 mL | 2.8950 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
